EV206
Based on 1 Customer Validation
EV206 is a Hsp70 binder and apoptosis inducer that binds to the N-terminal domain of Hsp70, promotes Hsp70 degradation via the ubiquitin-proteasome system, and reduces Hsp70 protein stability. EV206 induces apoptotic cell death, inhibits colony formation, and downregulates the expression of cancer stem cell-related markers in non-small cell lung cancer cells. EV206 inhibits the growth of H460 xenograft tumors in nude mice and can be used for the research of non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity : 99.62%
- CAS No.: 2247047-81-8
- Formula: C21H19N3O
- Molecular Weight:329.40
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
|
HSP70 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HGC-27 | IC50 |
1.05 μM
Compound: 6k
|
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
| LoVo | IC50 |
1 μM
Compound: 6k
|
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
| MGC-803 | IC50 |
0.06 μM
Compound: 6k
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
| RKO | IC50 |
0.38 μM
Compound: 6k
|
Antiproliferative activity against human RKO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human RKO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
| SGC-7901 | IC50 |
0.27 μM
Compound: 6k
|
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
| SW480 | IC50 |
0.38 μM
Compound: 6k
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37099835] |
In Vitro
EV206 (1-10 μM; 30 min at 4°C) binds directly to the full-length Hsp70 protein and its N-terminal domain, but not the C-terminal domain[1].
EV206 (up to 250 μM; equilibrated at 20°C) exhibits a higher binding affinity for the Hsp70 N-terminal domain (Kd = 16.60 μM) than for the C-terminal domain (Kd = 42.27 μM) in a fluorescence-based equilibrium binding assay[1].
EV206 (0.05-0.5 μM; 48 h) inhibits the viability of therapy-naïve H1299, A549, H460, H226B, and PC9 NSCLC cells with IC50 values below 0.5 μM after 48 h treatment, as measured by a crystal violet assay[1].
EV206 (0.05-0.5 μM; 48 h) inhibits the viability of drug-resistant H1299/CsR, H1299/PmR, H460/PcR, H226B/PcR, and PC9/ER NSCLC cells with IC50 values below 0.5 μM after 48 h treatment, as measured by a crystal violet assay[1].
EV206 (0.05-0.5 μM; 2-3 week culture) dose-dependently inhibits anchorage-dependent colony formation in H1299, A549, H460, H226B, and PC9 NSCLC cells[1].
EV206 (0.1-0.5 μM; 2-3 week culture) dose-dependently inhibits anchorage-independent colony formation in H1299, A549, H460, H226B, and PC9 NSCLC cells[1].
EV206 (0.1-0.5 μM; 48 h) dose-dependently induces apoptotic cell death (measured by increased sub-G1 population) in H1299, A549, H460, H226B, and PC9 NSCLC cells[1].
EV206 (0.1-0.5 μM; 48 h) dose-dependently induces apoptosis in H1299, A549, H460, H226B, and PC9 NSCLC cells, as shown by increased cleaved PARP and cleaved caspase-3 levels[1].
EV206 (0.1-0.5 μM; 48 h) dose-dependently reduces Hsp70 and Akt protein levels, but not Hsp90 protein levels, in H1299, A549, and H460 NSCLC cells[1].
EV206 (0.1-0.25 μM; 48 h) reduces Hsp70 protein stability in H460 NSCLC cells via the ubiquitin-proteasome system, as shown by the reversal of Hsp70 downregulation when co-treated with the proteasome inhibitor MG132 (10 μM for 6 h)[1].
EV206 (0.05-0.25 μM; 2-3 week culture) dose-dependently inhibits sphere formation (a marker of CSC-like phenotype) in H1299, A549, and H460 NSCLC cells[1].
EV206 (0.05-0.25 μM; 48 h) reduces aldehyde dehydrogenase (ALDH) activity, a marker of CSC-like phenotype, in H460 NSCLC cells[1].
EV206 (0.1 μM; during sphere culture) significantly downregulates the mRNA expression of CSC-associated markers POU5F1, NANOG, and SOX2 in H460 NSCLC spheres[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Therapy-naïve NSCLC cell lines (H1299, H460, A549, H226B, PC9)
-
Concentration:0.05, 0.1, 0.5 μM
-
Incubation Time:48 h
-
Result:Potently inhibited cell viability across all tested therapy-naïve NSCLC cell lines, with IC50 values of 0.35 μM (H1299), 0.23 μM (A549), 0.31 μM (H460), 0.38 μM (H226B), and 0.46 μM (PC9).
-
Cell Line:Drug-resistant NSCLC cell lines (H1299/CsR, H1299/PmR, H460/PcR, H226B/PcR, PC9/ER)
-
Concentration:0.05, 0.1, 0.5 μM
-
Incubation Time:48 h
-
Result:Dose-dependently inhibited cell viability across all tested drug-resistant NSCLC cell lines, with IC50 values of 0.30 μM (H1299/CsR), 0.20 μM (H1299/PmR), 0.35 μM (H460/PcR), 0.30 μM (H226B/PcR), and 0.46 μM (PC9/ER).
-
Cell Line:Therapy-naïve NSCLC cell lines (H1299, A549, H460, H226B, PC9)
-
Concentration:0.05, 0.1, 0.5 μM
-
Incubation Time:2-3 week culture
-
Result:Dose-dependently suppressed colony formation in all tested therapy-naïve NSCLC cell lines, with significant inhibition observed at all tested concentrations.
-
Cell Line:Therapy-naïve NSCLC cell lines (H1299, A549, H460, H226B, PC9)
-
Concentration:0.1, 0.25, 0.5 μM
-
Incubation Time:2-3 week culture
-
Result:Dose-dependently suppressed soft agar colony formation in all tested therapy-naïve NSCLC cell lines, with significant inhibition observed at all tested concentrations.
-
Cell Line:Therapy-naïve NSCLC cell lines (H1299, A549, H460)
-
Concentration:0.1, 0.25, 0.5 μM
-
Incubation Time:48 h
-
Result:Dose-dependently decreased Hsp70 and Akt protein levels across all tested therapy-naïve NSCLC cell lines.
Did not alter Hsp90 protein levels across all tested therapy-naïve NSCLC cell lines.
-
Cell Line:H460 NSCLC cells
-
Concentration:0.1, 0.25 μM (EV206); 10 μM (MG132)
-
Incubation Time:48 h (EV206); final 6 h (MG132)
-
Result:Induced downregulation of Hsp70 protein levels in H460 cells.
Had this effect significantly blunted by co-treatment with MG132, indicating the effect is mediated via the ubiquitin-proteasome system.
-
Cell Line:H460 NSCLC spheres
-
Concentration:0.1 μM
-
Incubation Time:during sphere culture
-
Result:Caused a marked decrease in the mRNA expression of POU5F1 (Oct4), NANOG, and SOX2, all CSC-associated markers.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (6-week-old; male and female; H460 NSCLC xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; 16 days
-
Result:Inhibited H460 tumor xenograft growth.
Showed no significant changes in mouse body weight relative to vehicle controls.
Chemical Information
-
CAS No. 2247047-81-8
-
Appearance Solid
-
Molecular Weight 329.40
-
Formula C21H19N3O
-
Color White to off-white
-
SMILES
O=C1C2=C(C=CC=C2)N(CC=C)C(N1CC3)C4=C3C5=CC=CC=C5N4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (151.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0358 mL | 15.1791 mL | 30.3582 mL | 75.8956 mL |
| 5 mM | 0.6072 mL | 3.0358 mL | 6.0716 mL | 15.1791 mL | |
| 10 mM | 0.3036 mL | 1.5179 mL | 3.0358 mL | 7.5896 mL | |
| 15 mM | 0.2024 mL | 1.0119 mL | 2.0239 mL | 5.0597 mL | |
| 20 mM | 0.1518 mL | 0.7590 mL | 1.5179 mL | 3.7948 mL | |
| 25 mM | 0.1214 mL | 0.6072 mL | 1.2143 mL | 3.0358 mL | |
| 30 mM | 0.1012 mL | 0.5060 mL | 1.0119 mL | 2.5299 mL | |
| 40 mM | 0.0759 mL | 0.3795 mL | 0.7590 mL | 1.8974 mL | |
| 50 mM | 0.0607 mL | 0.3036 mL | 0.6072 mL | 1.5179 mL | |
| 60 mM | 0.0506 mL | 0.2530 mL | 0.5060 mL | 1.2649 mL | |
| 80 mM | 0.0379 mL | 0.1897 mL | 0.3795 mL | 0.9487 mL | |
| 100 mM | 0.0304 mL | 0.1518 mL | 0.3036 mL | 0.7590 mL |